Solid Biosciences (SLDB) Competitors $4.98 +0.11 (+2.18%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$5.03 +0.05 (+0.98%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. OCUL, VERA, BHVN, ETNB, ANIP, JANX, MESO, EWTX, TVTX, and BGMShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Janux Therapeutics (JANX), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Its Competitors Ocular Therapeutix Vera Therapeutics Biohaven 89BIO ANI Pharmaceuticals Janux Therapeutics Mesoblast Edgewise Therapeutics Travere Therapeutics BGM Group Solid Biosciences (NASDAQ:SLDB) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership. Do analysts prefer SLDB or OCUL? Solid Biosciences presently has a consensus price target of $15.10, suggesting a potential upside of 203.46%. Ocular Therapeutix has a consensus price target of $17.33, suggesting a potential upside of 85.19%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SLDB or OCUL? In the previous week, Solid Biosciences had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.87 beat Solid Biosciences' score of 0.36 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SLDB or OCUL? Solid Biosciences has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Do insiders and institutionals hold more shares of SLDB or OCUL? 81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SLDB or OCUL more profitable? Solid Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. Ocular Therapeutix's return on equity of -59.92% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -68.15% -55.33% Ocular Therapeutix -323.09%-59.92%-41.98% Which has higher earnings & valuation, SLDB or OCUL? Solid Biosciences has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid Biosciences$8.09M47.67-$124.70M-$2.99-1.66Ocular Therapeutix$63.72M23.40-$193.51M-$1.15-8.14 SummarySolid Biosciences beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$389.90M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-1.6621.5627.4320.23Price / Sales47.67281.76420.79118.64Price / CashN/A42.7336.8958.07Price / Book1.457.518.045.67Net Income-$124.70M-$55.05M$3.18B$249.13M7 Day Performance5.42%4.61%2.88%3.28%1 Month Performance17.08%4.72%3.69%5.56%1 Year Performance-15.23%5.92%36.15%21.12% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.3141 of 5 stars$4.98+2.2%$15.10+203.5%-16.6%$389.90M$8.09M-1.66100Gap UpOCULOcular Therapeutix3.9451 of 5 stars$9.24+0.5%$17.33+87.6%+39.9%$1.47B$63.72M-8.04230VERAVera Therapeutics3.5278 of 5 stars$22.96-1.5%$65.00+183.1%-31.9%$1.46BN/A-7.6540BHVNBiohaven3.4252 of 5 stars$14.30-0.2%$58.46+309.0%-56.7%$1.46BN/A-1.53239ETNB89BIO1.9454 of 5 stars$9.79+0.3%$26.43+169.9%+35.6%$1.43BN/A-2.9040Positive NewsANIPANI Pharmaceuticals3.7185 of 5 stars$65.74-0.3%$80.13+21.9%+7.4%$1.42B$674.07M-51.76600JANXJanux Therapeutics1.848 of 5 stars$23.27+0.1%$95.25+309.4%-36.3%$1.37B$10.59M-17.0530MESOMesoblast2.3857 of 5 stars$10.71+1.5%$18.00+68.1%+58.6%$1.37B$5.90M0.0080Positive NewsEWTXEdgewise Therapeutics2.4951 of 5 stars$13.00-9.3%$39.78+206.1%-29.1%$1.37BN/A-8.3860News CoverageAnalyst RevisionGap DownTVTXTravere Therapeutics3.2036 of 5 stars$14.97+0.1%$32.14+114.7%+88.9%$1.33B$233.18M-5.33460Analyst ForecastAnalyst RevisionBGMBGM GroupN/A$13.08+0.6%N/AN/A$1.28B$25.10M0.00298 Related Companies and Tools Related Companies Ocular Therapeutix Competitors Vera Therapeutics Competitors Biohaven Competitors 89BIO Competitors ANI Pharmaceuticals Competitors Janux Therapeutics Competitors Mesoblast Competitors Edgewise Therapeutics Competitors Travere Therapeutics Competitors BGM Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
